Lisa Carey
Deputy Director of Clinical Sciences, Lineberger Comprehensive Cancer Center · University of North Carolina Hospitals
Credentials: · · ·
History
PresentLineberger Comprehensive Cancer Center · University of North Carolina Hospitals
- 1993–1995
- 1990–1993
- 1986–1990
- 1982–1986
Research
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
JAMA · 2006 · First of 17 authors · Corresponding · 2,935 citations
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
Clinical Cancer Research · 2007 · First of 10 authors · Corresponding · 1,643 citations
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine · 2021 · 1,378 citations
73 papers
49 papers
42 papers
39 papers
- AW
38 papers
37 papers
34 papers
- CH
32 papers
Grants
- 2025–2030
Elucidating the Molecular Mechanisms of Metastasis Organ Tropism
National Cancer Institute · U01
PI · $1.3M · Univ of North Carolina Chapel Hill
- 2019–2030
National Cancer Institute · R01
Contact PI · $4M · Univ of North Carolina Chapel Hill
- 1997–2029
National Cancer Institute · P50
PI · $12.7M · Univ of North Carolina Chapel Hill
- 2019–2027
UNC Lead Academic Participating Site
National Cancer Institute · UG1
Contact PI · $3.5M · Univ of North Carolina Chapel Hill
Clinical trials
- 2026–2031
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Principal investigator · Recruiting · Phase 2
UNC Lineberger Comprehensive Cancer Center
- 2022–2026
Principal investigator · Terminated · Phase 3
SOLTI Breast Cancer Research Group
- 2018–2019
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
Principal investigator · Terminated · Early phase 1
UNC Lineberger Comprehensive Cancer Center
- 2018–2030
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
Principal investigator · Recruiting
UNC Lineberger Comprehensive Cancer Center